Fig. 8. miR-3163 enhances the antitumor effect of sorafenib on the subcutaneous growth of MHCC97-H cells by targeting ADAM-17.
MHCC97-H cells transfected with vectors (control miRNA, miR-3163, miR-3163 + ADAM-17, miR-3163 + ADAM-17Mut, or miR-3163 + NICD) were injected into nude mice to form subcutaneous tumors. The mice received oral administration of 2 mg/kg dose of sorafenib and were harvested to collect tumor tissues. The results are shown as images of subcutaneous tumor tissues (a), tumor volumes (b), tumor weights (c), inhibition rates according to tumor volumes (d), or inhibition rates according to tumor weights (e). The expression level of downstream factors Notch pathways: pro-survival factors (f) or EMT-related factors (g) in the represented subcutaneous tumors (the No. 1, 5 and 9 of tumors) of Fig. 8 were examined by western blotting experiments (f, g). *P < 0.05